Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch

Printed: July 30, 2020 at 5: 53 a.m. ET

Johnson & Johnson
JNJ,
-0.19%
mentioned Thursday that its lead vaccine candidate safe against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-scientific compare. The vaccine offered a magnificent immune response as demonstrated by “neutralizing antibodies,” successfully battling subsequent infection and offering complete or near-complete security within the lungs from the virus in non-human primates, the firm mentioned. Per the strength of the records, a Portion 1/2a first-in-human scientific trial of the vaccine candidate, Ad26.COV2.S, in healthy volunteers, has now commenced within the United States and Belgium, the firm mentioned. Discussions are underway with partners with the target to begin up a pivotal Portion 3 scientific trial of the one vaccine dose versus placebo in September, pending the intervening time knowledge of the Portion 1 and a pair of trials and approval of regulators, Johnson & Johnson mentioned.